Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-TT given alone or co-administered with Cervarix and/or Boostrix in female adolescents and young adults
2012-001876-13Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine, human papillomavirus type 16 L1 capsid protein antigen and acellular pertussis vaccine in meningococcal disease (3 arms), sponsored by GSK. Primary endpoints: rSBA-MenA GMT, rSBA-MenC GMT and 2 more. Started Sep 2012; status: completed.
02
Drugs
meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccinehuman papillomavirus type 16 L1 capsid protein antigenacellular pertussis vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2012-001876-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001876-13.